The addition of immunotherapy and targeted therapies to the NCCN guidelines in bile duct cancer means that tumor mutation profiling is now called for to guide treatment decisions.
Cholangiocarcinoma Guideline Updates 2021 | articles
The EMA panel's nod pemigatinib in bile duct cancer is the latest positive news for the targeted therapy after its FDA approval and appearance in the NCCN Guidelines.
Advertisement
Advertisement
Trending on AJMC
1
Guideline-Directed Medical Therapies in Heart Failure
2
Responsible Use of Energy-Based Treatments on Skin of Color: Eliot F. Battle, MD
3
Coordinating Medications for Women With Arrhythmia: Lindsey Valenzuela, PharmD
4
Collaboration in Heart Failure Treatment
5
